'Are you guys out of vi­rol­o­gy?': Not hard­ly, says Gilead ex­ecs, as they buy a late-stage drug com­pa­ny for $1.7B

Gilead has turned the spot­light in M&A and BD to can­cer since Dan O’Day took the top spot at the com­pa­ny. But to­day, it’s vi­rol­o­gy’s turn to take cen­ter stage.

The CEO has struck a deal to buy out Ger­many’s MYR GmbH, a pri­vate­ly held biotech which has an ad­vanced drug for he­pati­tis delta virus that fits well with their fo­cus on he­pati­tis B, for $1.7 bil­lion. Most of that is in cash, with $360 mil­lion on the ta­ble for an FDA ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER